Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Must have received: androgen deprivation therapy

Participants must have had a prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L).

Must have received: androgen receptor-directed therapy (enzalutamide, abiraterone, apalutamide, darolutamide)

Prior progression on at least one ARDT (enzalutamide, abiraterone, apalutamide, darolutamide).

Must have received: taxane — mCRPC

Prior treatment with only one taxane therapy in the mCRPC setting. Note: Prior treatment with docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is permitted; however, participants must have also received one, and only one, taxane therapy in the mCRPC setting.

Cannot have received: STEAP1-targeted therapy

Prior six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted therapy.

Cannot have received: Prostate-Specific Membrane Antigen radioligand therapy

Exception: unless participants received < 2 cycles of therapy

Prior Prostate-Specific Membrane Antigen (PSMA) radioligand therapy (RLT) within 3 months of the first dose of study treatment unless participants received < 2 cycles of therapy.

Cannot have received: radionuclide therapy (Radium-223)

Prior radionuclide therapy (Radium-223) within 2 months of first dose of study treatment.